LMR Partners’s Iovance Biotherapeutics IOVA Stock Holding History

LMR Partners’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$145K	Hold	41,211	–	–	﹤0.01%	1226
2025 Q4	$113K	Hold	41,211	–	–	﹤0.01%	1334
2025 Q3	$89.4K	Hold	41,211	–	–	﹤0.01%	1287
2025 Q2	$70.9K	Hold	41,211	–	–	﹤0.01%	1197
2025 Q1	$137K	Hold	41,211	–	–	﹤0.01%	1106
2024 Q4	$305K	Hold	41,211	–	–	﹤0.01%	901
2024 Q3	$387K	Sell	41,211 -20,000	-33%	-$189K	﹤0.01%	874
2024 Q2	$491K	Sell	61,211 -60,400	-50%	-$647K	﹤0.01%	773
2024 Q1	$1.8M	Buy	121,611 +80,400	+195%	+$936K	0.02%	568
2023 Q4	$335K	Hold	41,211	–	–	﹤0.01%	688
2023 Q3	$188K	Hold	41,211	–	–	﹤0.01%	644
2023 Q2	$290K	Hold	41,211	–	–	﹤0.01%	555
2023 Q1	$252K	Sell	41,211 -10,000	-20%	-$69K	﹤0.01%	830
2022 Q4	$327K	Hold	51,211	–	–	0.01%	944
2022 Q3	$491K	Hold	51,211	–	–	0.01%	888
2022 Q2	$565K	Hold	51,211	–	–	0.01%	887
2022 Q1	$853K	Sell	51,211 -10,000	-16%	-$155K	0.01%	869
2021 Q4	$1.17M	Hold	61,211	–	–	0.01%	655
2021 Q3	$1.51M	Buy	61,211 +39,265	+179%	+$925K	0.02%	523
2021 Q2	$571K	Buy	+21,946	New	+$570K	0.01%	645
2020 Q4	–	Sell	-49,504	Closed	-$1.63M	–	553
2020 Q3	$1.63M	Sell	49,504 -8,736	-15%	-$268K	0.03%	171
2020 Q2	$1.6M	Buy	+58,240	New	+$1.91M	0.04%	292

Other funds holding IOVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

LMR Partners's IOVA Position: Q1 2026 in Review

LMR Partners held its Iovance Biotherapeutics (IOVA) position steady in Q1 2026 at 41,211 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #1226.

LMR Partners first reported a position in IOVA in Q2 2020 and has held it in 22 quarters since. The position peaked at $1.8M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

LMR Partners held 41,211 shares of Iovance Biotherapeutics worth $145K as of Q1 2026.
LMR Partners left its Iovance Biotherapeutics share count unchanged in Q1 2026.
Iovance Biotherapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1226 holding.
LMR Partners first reported a position in Iovance Biotherapeutics in Q2 2020 and has held it in 22 quarters since.
LMR Partners's Iovance Biotherapeutics position peaked at $1.8M in Q1 2024.
285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.